Pharma Q2 Preview: Cipla to see steady qtr; higher profit growth for DRL https://ift.tt/6GwDM5T could deliver healthy growth of 5% in the Indian business in the second quarter, but the US business is likely to witness pressure on account of lower Albuterol Sulphate sales. Revenue for the quarter is likely to grow at 13% year-on-year (YoY), according to an average estimate of three brokerages, and net profit for the same period is expected to rise around 19% YoY.
Thursday, October 26, 2023
Subscribe to:
Post Comments (Atom)
Posts
No comments:
Post a Comment